MRI contrast dye may skew brain scans, study finds
NCT ID NCT04906941
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at how gadolinium, a dye used in MRI scans, changes the QSM signal in the brain's white matter. 73 patients with inflammatory central nervous system conditions had MRI scans before and after receiving gadolinium. The goal was to measure any differences in the signal, which could help doctors better understand and interpret future scans.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- gadolinium (contrast agent)
- What this could lead to
- If successful, this could help doctors interpret MRI scans more accurately in patients with white matter disease.
- What could go wrong
- This is a small, completed observational study, not a treatment trial. Results may not apply to all patients or MRI machines.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLAMMATORY CNS PATHOLOGY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hhopital fondation adolphe de rothschild
Paris, Paris, 75019, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.